This demonstrates that Nivolumab and Ipilimumab synergistically promote T-cell anti-tumor activity through complementary mechanisms of action, which provides a clinical experimental basis for CTLA-4 inhibitors combined with PD-1 inhibitors in the treatment of MSI-H/dMMR mCRC (43). This evidence concerns the gene PDCD1 and neoplasm.